VHIO´s 2015 Scientific Report launched: in print, extended version online, and interactive PDF

The Worldwide Innovative Network (WIN) in personalized cancer medicine consortium, of which the Vall d´Hebron Institute of Oncology (VHIO) is…

Considering cancer from an evolutionary perspective in order to better understand its vast complexity and clonal dynamics is undoubtedly opening…

One of Spain´s major department store chains, El Corte Inglés, last week strengthened its collaboration with the Spanish Association against…

The group led by Dr Joan Seoane, ICREA Research Professor at the VHIO, has carried out the research in glioma, the most common malignant brain tumor. The study published describes how to identify cells with characteristics of stem cells in the interior of the glioma. These cells, known as Glioma initiating cells (GICs), are responsible for initiating the glioma and also for it reappearing after surgical removal.
 

Latest research at VHIO confirms 4 subgroups of HER2+ breast cancer with different molecular characteristics The diagnostic test for these…

Officially announced yesterday, the Government of the Generalitat of Catalonia has revealed the thirteen recipients of the Josep Trueta Medal…

The phase III study, published in the prestigious scientific journal, The Lancet, in which researchers at the Vall d´Hebron University…

First new treatment to be approved for pancreatic cancer in nearly seven years, highlighting the challenges and unmet needs in…

Supported by the European Commission´s 7th Framework Programme of Research and Development, and coordinated by Catharine West, University of Manchester,…

• The new study published in Cancer Discovery, the flagship journal of the American Association of Cancer Research (AACR), involving…

Cancer researchers, oncologists and international pharmaceutical company join forces to test a new investigational drug for breast cancer Barcelona, 05…

Barcelona, 18 November 2015.-According to a second independent, annual benchmark evaluation of the Spanish healthcare sector, Monitor de Reputación Sanitaria…

Findings reported from the open-label, single-group, and mulitcenter phase II PAMELA trial, published last week in The Lancet Oncology*, have…

VHIO is delighted to announce that Charles M. Perou, May Goldman Shaw Distinguished Professor of Molecular Oncology, professor of genetics,…